The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Wright P

Untoward effects associated with practolol administration: oculomucocutaneous syndrome.

British medical journal. 1975;1(5958):595-8

Hall DR, Morrison JB, Edwards FR

Pleural fibrosis after practolol therapy.

Thorax. 1978;33(6):822-4

Lemola M, Ahonen A

[Bilateral pleural effusion after practolol (author's transl)].

Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis. 1977;66(22):676-8

MacKAY AD, Axford AT

Letter: Pleural effusions after practolol.

Lancet (London, England). 1976;1(7950):89

Fleming HA, Hickling P

Letter: Pleural effusions after practolol.

Lancet (London, England). 1975;2(7946):1202